Biotech grants
SBIR funding for therapeutics, platforms and biomanufacturing
Biotech is the most competitive part of the federal portfolio and the most rewarding. NIH alone commits well over $1.2B a year through SBIR/STTR, and NSF funds biotechnology platforms that are too early for a disease-specific institute. Our writers hold PhDs in molecular biology, immunology and bioengineering, so your preclinical package is translated by someone who has run the assays.
$240M+ won by our team
PhD-level specialists, never a template or an AI tool.
Agencies funding biotech
- ARPA-H
Programs that fit biotech companies
NIH SBIR/STTR
Institute-specific topics, three receipt dates a year, $314K Phase I.
NSF SBIR: Biotechnology
Open-topic platform technologies, starting with a Project Pitch.
ARPA-H
High-risk programmatic funding for breakthrough biomedical approaches.
What reviewers actually score
- A falsifiable Phase I hypothesis with quantitative go/no-go milestones
- Honest treatment of biological risk rather than optimistic hand-waving
- A regulatory and reimbursement pathway that a non-specialist reviewer can follow
Where we work in biotech
Relevant client wins
Grants our team has won for companies solving comparable technical problems.
FASST
Life sciences: pharmaceutical manufacturing
≈$888K(£699,030)
£699,030 for robotic polypill manufacturing
Innovate UK grantMediMusic
Life sciences: digital therapeutics
≈$233K(£183,682)
£183,682 for AI-enhanced music therapy
Innovate UK grantHuman-centric digital therapeutic platform
Life sciences: digital therapeutics
≈$100K(£79,000)
£79K secured for early-stage validation
Fund your biotech R&D
Talk to us about your federal funding plans and we'll help you make it happen through effective, results-driven grant writing.